PO Box 9300
2312 HSC South
1 Medical Center Drive
- View Website
- West Virginia University School of Medicine
Non-Programmatically Aligned MBRCC Members
Ten Most Recent:
Prostasin may contribute to chemoresistance, repress cancer cells in ovarian cancer, and is involved in the signaling pathways of CASP/PAK2-p34/actin.
Yan BX, Ma JX, Zhang J, Guo Y, Mueller MD, Remick SC, Yu JJ.
Cell Death Dis. 2014;5:e995
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.
Younis IR, George DJ, McManus TJ, Hurwitz H, Creel P, Armstrong AJ, Yu JJ, Bacon K, Hobbs GR, Peer CJ, Petros WP.
Cancer Chemother Pharmacol. 2014;73(5):991-997.
Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of Chinese pre-clinical and clinical profile and emerging mechanistic studies.
Yu JJ, Yang X, Song Q, Mueller MD, Remick SC.
Anticancer Res. 2014;34(1):455-463.
PSP94 contributes to chemoresistance and its peptide derivative PCK3145 represses tumor growth in ovarian cancer.
Yan BX, Ma JX, Zhang J, Guo Y, Riedel H, Mueller MD, Remick SC, Yu JJ.
Oncogene. 2013; [Epub ahead of print]
Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.
Guo Y, Fu P, Zhu H, Reed E, Remick SC, Petros WP, Mueller MD, Yu JJ.
Oncol Rep. 2012;27(1):286-292.
The role of Wild-Type p53 in cisplatin-induced Chk2 phosphorylation and the inhibition of platinum resistance with a Chk2 inhibitor.
Liang XB, Guo Y, Figg WD, Fojo AT, Mueller MD, Yu JJ.
Chemother Res Pract. 2011;2011:715469
A polymorphic variant of AFAP-110 enhances cSrc activity.
Clump DA, Yu JJ, Cho Y, Gao R, Jett J, Zot HM, Cunnick JM, Snyder B, Clump AC, Dodrill M, Gannett PM, Coad JE, Shurina R, Figg WD, Reed E, Flynn DC.
Transl Oncol. 2010;3(4):276-285.
HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma.
Yu JJ, Fu PF, Pink JJ, Dawson D, Wasman JK, Orem JN, Mwanda WO, Zhu HL, Liang XB, Guo Y, Petros WP, Mitsuyasu RT, Wabinga H, Remick SC.
PLoS One. 2010;5(5):e10477
Gene expression patterns in the histopathological classification of epithelial ovarian cancer.
Zhu H, Yu JJ.
Exp Ther Med. 2010;1(1):187-192.
EGFR artifactual mutations associated with two DNA sequencers.
Yu JJ, Flynn DC.
Non-Programmatically Aligned Cancer Center Members
Thirty years after FDA approval, cisplatin and its homologs continue to play a key role in treating solid tumors. Today, they are used as cancer therapeutic regimens for patients with adenocarcinoma, breast, cervical, colorectal, endometrial, esophageal, gastrointestinal, head & neck, lung, melanoma, non-hodgkins lymphoma, ovarian, pancreatic and testicular cancers. However, platinum-based chemotherapy often results in relatively low survival due to the development of drug resistance. Enhanced repair of platinum-induced DNA-adduct has been suggested as one of the major mechanisms of acquired platinum resistance. Recent research indicates that alteration of the DNA repair system resulting in reduced apoptosis is the leading mechanism of increased DNA repair and platinum-drug resistance. Our goal is to block the DNA repair pathway genes, thereby enhancing cisplatin sensitivity, making cancer chemotherapy more effective.